Similar to our previous findings [25], combined p53 siRNA and EGCG treatment minimized the activation of the anti-apoptotic genes (such as BAG3, XIAP, and RIPK2) related to treatment resistance, which may further increase cancer cell sensitivity to treatment. Here, TP53 is linked to cancer.